1. How I Approach Smoldering Myeloma (Vaxman and Gertz):https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM:Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/ 3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):https://pubmed.ncbi.nlm.nih.gov/36067617/ 4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):https://pubmed.ncbi.nlm.nih.gov/31652094/ 5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739 6. Current Clinical Trial Landscape in Smoldering Myeloma:https://pubmed.ncbi.nlm.nih.gov/34114943/ 7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event? https://pubmed.ncbi.nlm.nih.gov/35190659/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related